Vir Biotechnology, Inc. (VIR) — Analyst outlook / Analyst consensus target is. Based on 12 analyst ratings, the consensus is bullish — 10 Buy, 2 Hold.
The consensus price target is $21.29 (low: $18.00, high: $30.00), representing an upside of 111.8% from the current price $10.05.
Analysts estimate Earnings Per Share (EPS) of $-3.88 and revenue of $0.07B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.83 vs est $-3.88 (beat +1.3%). 2025: actual $-3.16 vs est $-3.35 (beat +5.8%). Analyst accuracy: 96%.
VIR Stock — 12-Month Price Forecast
$21.29
▲ +111.84% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Vir Biotechnology, Inc., the average price target is $21.29, with a high forecast of $30.00, and a low forecast of $18.00.
The average price target represents a +111.84% change from the last price of $10.05.
Highest Price Target
$30.00
Average Price Target
$21.29
Lowest Price Target
$18.00
VIR Analyst Ratings
Buy
Based on 12 analysts giving stock ratings to Vir Biotechnology, Inc. in the past 3 months
EPS Estimates — VIR
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$3.83
vs Est –$3.88
▲ 1.4% off
2025
Actual –$3.16
vs Est –$3.35
▲ 6.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — VIR
61%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.074B
vs Est $0.069B
▲ 7.5% off
2025
Actual $0.069B
vs Est $0.021B
▲ 69.7% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
